New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 29, 2014
06:49 EDTJNJ, VRXJ&J among firms fined for price-fixing case in China, Bloomberg says
Johnson & Johnson (JNJ) and Valeant's (VRX) Bausch & Lomb were among the companies that were fined a combined $3M for price-fixing in the country’s contact lens and eye-glass market, according to Bloomberg, citing a statement from China’s National Development and Reform Commission on its website. Reference Link
News For JNJ;VRX From The Last 14 Days
Check below for free stories on JNJ;VRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 2, 2014
09:07 EDTVRXAllergan filed answer in federal court reponding to Valeant, Pershing claims
Subscribe for More Information
August 31, 2014
14:04 EDTJNJWorldwide Business Research to hold a conference
Subscribe for More Information
August 28, 2014
17:42 EDTJNJJ&J begins sales process for its medical device unit Cordis, WSJ says
Subscribe for More Information
August 27, 2014
13:33 EDTVRXValeant, Pershing suit against Allergan expedited, WSJ says
After a hearing on Wednesday morning in Delaware Chancery Court, a judge has expedited a lawsuit from Valeant (VRX) and Pershing Square's William Ackman against Allergan (AGN), says the Wall Street Journal. Last week Valeant and Ackman sued Allergan to quickly schedule a special meeting to decide on the fate of Allergan's board members, added the Wall Street Journal. Reference Link
August 26, 2014
20:04 EDTVRXAllergan requests block to Ackman, Valeant votes, announces Special Meeting date
Subscribe for More Information
16:45 EDTVRXAllergan schedules special meeting on takeover for December 18, WSJ says
Subscribe for More Information
August 25, 2014
08:27 EDTJNJJanssen Affiliate Cilag acquires Covagen, terms not disclosed
Subscribe for More Information
07:03 EDTJNJVIVUS acquires patents from Janssen Pharmaceuticals
VIVUS (VVUS) announced the acquisition of a group of patents from Janssen Pharmaceuticals (JNJ) covering uses of topiramate as monotherapy and in combination with other pharmaceutical agents to treat a variety of medical conditions. Janssen has agreed to dismiss the lawsuit it brought against VIVUS on August 22, 2014 in the U.S. District Court for the District of Delaware. VIVUS will pay a one-time upfront fee and a royalty to Janssen on Qsymia product sales for an assignment of these topiramate-related patents owned by Janssen. VIVUS has an option to buy out the royalty for a predetermined amount.
August 22, 2014
19:02 EDTVRXAllergan confirms Pershing written request, board views Valeant offer inadequate
Subscribe for More Information
18:33 EDTVRXPershing Square submits requisite requests from Allergan holders to call meeting
Subscribe for More Information
09:33 EDTVRXValeant to request today special meeting of Allergan holders, CNBC reports
Valeant (VRX) will deliver today a request of 30%-plus of Allergan (AGN) shareholders for a special meeting, CNBC's David Faber reports, citing sources.
06:49 EDTVRXJudge rejects Allergan inquiry to quicken insider trading case, Reuters says
Subscribe for More Information
06:45 EDTVRXJudge refuses to prevent special Allergan shareholder meeting, NY Times says
Subscribe for More Information
August 21, 2014
09:42 EDTVRXValeant to sell Precision's assets related to two acne treatments
Subscribe for More Information
05:42 EDTJNJIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
August 20, 2014
17:59 EDTVRXAllergan talks with Salix in defense tactic said to be dormant, Bloomberg says
Subscribe for More Information
17:35 EDTVRXAllergan said to explore options outside of Salix acquisition, Bloomberg says
Subscribe for More Information
10:53 EDTVRXAnalysts say Salix takeover would boost Allergan
Subscribe for More Information
09:46 EDTVRXAllergan merger deal not imminent, CNBC's Faber reports
An acquisition by Allergan (AGN) is not imminent, CNBC's David Faber reports. Salix (SLXP) and Jazz Pharmaceuticals (JAZZ) are said to be potential targets of the company, Faber adds. Valeant (VRX) could announce over the next few days that it has enough votes to call for a special meeting, the reported said.
07:07 EDTVRXSome Valeant shareholders express uncertainty over Allergan deal, Reuters says
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use